Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propyl Phosphate SCHEMBL28164710 | 0.95 | LPAR3 (0.52) | LPAR3LPAR2LPAR1TYMSS1PR2 | |
| SCHEMBL18631699 | 0.84 | LPAR3 (0.50) | LPAR3LPAR2LPAR1TYMSS1PR2 | |
| SCHEMBL11650160 | 0.81 | LPAR3 (0.56) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL1973213 | 0.81 | LPAR3 (0.46) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL11506131 | 0.79 | LPAR3 (0.65) | LPAR3LPAR2LPAR1 | |
| SCHEMBL9124138 | 0.79 | LPAR3 (0.44) | LPAR3LPAR2LPAR1 | |
| Hydrochloric Acid SCHEMBL2150786 | 0.79 | LPAR3 (0.44) | LPAR3LPAR2LPAR1 | |
| SCHEMBL7270141 | 0.79 | LPAR3 (0.44) | LPAR3LPAR2LPAR1 | |
| SCHEMBL28913382 | 0.78 | LPAR3 (0.69) | LPAR3LPAR2LPAR1 | |
| SCHEMBL39671 | 0.77 | LPAR3 (0.60) | LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521783-B1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | claimed |
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10781449-B2 | Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| CN-103917647-B | Methods and compositions for neuroprotection | 夸克制药公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-2504435-B1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10421962-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | NITTO DENKO CORP (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3536343-A1 | SKIN FIBROSIS TREATMENT AGENT | Nitto Denko Corporation (JP) | 2019-09-11 | — | — | EP | disclosed |
| US-20190040385-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TARGETING P53 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-2509991-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2504435-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | Quark Pharmaceuticals, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012078536-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142754-A1 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | QUARK PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2012044620-A2 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011163436-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Technical Corporation | 2011-07-21 | — | — | US | disclosed |
| WO-2011085056-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011072082-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011066475-A1 | SIRNA COMPOUNDS COMPRISING TERMINAL SUBSTITUTIONS | QUARK PHARMACEUTICALS, INC. (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | HSPA1A, HSPH1, HSPA8 | LPAR3 3223/4885LPAR2 4209/4885LPAR1 4282/4885 |
| US-10195145-B2 | Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier | HSPH1, FABP1, LRAT | LPAR3 257/4885LPAR2 413/4885LPAR1 411/4885 |
| US-20190275158-A1 | SKIN FIBROSIS TREATMENT AGENT | COL1A1, COLGALT1, COL14A1 | LPAR3 496/4885LPAR2 165/4885LPAR1 226/4885 |
| US-20120142754-A1 | MODULATION OF TIMP1 AND TIMP2 EXPRESSION | MMP1, TIMP3, RNASE1 | LPAR3 2744/4885LPAR2 1071/4885LPAR1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.